ReNeuron Group Plc (LON:RENE)‘s stock had its “corporate” rating reaffirmed by stock analysts at N+1 Singer in a research note issued on Tuesday.
About ReNeuron Group Plc
ReNeuron Group plc is a clinical-stage company. The Company, through its subsidiaries, is engaged in researching and developing cell-based therapies. The Company’s products are allogeneic. Its CTX stem cell therapy is used for the treatment of patients left disabled by the effects of a stroke. Its human retinal progenitor cells (hRPC) stem cell candidate is used for the treatment of retinitis pigmentosa (RP).
What are top analysts saying about ReNeuron Group Plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for ReNeuron Group Plc and related companies.